ismelin
Pharmaranks rates Ismelin 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Ismelin (Guanethidine Monosulfate) is a medication used to treat Hypertension.
Guanethidine Monosulfate · by Novartis
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Guanethidine Monosulfate
- Form
- Tablet
- Strength
- Guanethidine Monosulfate EQ 10MG Sulfate · Guanethidine Monosulfate EQ 25MG Sulfate
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- hypertension
- Manufacturer
- Novartis
- FDA application
- NDA012329
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Ismelin treat?
- Ismelin (Guanethidine Monosulfate) may be used to treat hypertension, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Ismelin rated?
- pharmaranks gives Ismelin a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Ismelin?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Ismelin. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Ismelin?
- Ismelin is marketed by Novartis. You can see Novartis's full profile, rating, and other products on pharmaranks.
- Is Ismelin a brand-name or generic drug?
- Ismelin is a brand-name product with the active ingredient Guanethidine Monosulfate.
- Is Ismelin available over the counter?
- No. Ismelin is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Ismelin come in?
- Ismelin is currently marketed as tablet, per the FDA's National Drug Code Directory.
- Is Ismelin FDA-registered?
- Ismelin is on record with the U.S. FDA under application number NDA012329. You can verify this on its official FDA label.
- Has Ismelin been recalled by the FDA?
- Ismelin has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Ismelin safe?
- There's no single safe-or-not verdict. pharmaranks gives Ismelin a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about GUANETHIDINE MONOSULFATE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 2 reports naming GUANETHIDINE MONOSULFATE — the active ingredient in Ismelin, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- blood pressure inadequately controlled1 reports
- nephrolithiasis1 reports
- renal tubular acidosis1 reports
- ureteric obstruction1 reports
- wheezing1 reports
Read these as a signal, not a rate. A report does not mean GUANETHIDINE MONOSULFATE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
amlodipine besylate
Amlodipine Besylate
atacand
Candesartan Cilexetil
bumex
Bumetanide
cardene
Nicardipine Hydrochloride
cardene in 0.83% sodium chloride in plastic container
Nicardipine Hydrochloride
cardene in 0.86% sodium chloride in plastic container
Nicardipine Hydrochloride
Compare Ismelin head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
ismelin
70/100